CD274 and urothelial carcinoma: As the assay adopted in the present study was developed in conjunction with therapeutic regimens for uroepithelial carcinomas only, our results might better reflect actual therapeutic indications for PD-L1 status than those of previous studies because a higher cut-off value was applied.